{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"1.45","upperLimit":"4.14","value":"3.81"},{"groupId":"OG001","lowerLimit":"13.71","upperLimit":"15.88","value":"14.63"},{"groupId":"OG002","lowerLimit":"6.25","upperLimit":"10.03","value":"7.68"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"3"},{"groupId":"OG001","value":"3"},{"groupId":"OG002","value":"4"}],"units":"Participants"}],"description":"Dose Expansion. PFS is defined as the time from randomization until objective tumor progression or death. Progressive Disease (PD): At least a 20% increase in the sum of the diameters of target lesions, taking as reference the smallest sum on study (this includes the baseline sum if that is the smallest on study). In addition to the relative increase of 20%, the sum must also demonstrate an absolute increase of at least 5 mm. (Note: the appearance of one or more new lesions is also considered progressions).","dispersionType":"95% Confidence Interval","groups":[{"description":"Dose Escalation: Level 1 dose of 80 mg enzalutamide (orally), with standard doses of cisplatin and gemcitabine via intravenous (IV).","id":"OG000","title":"Dose Escalation: Level 1 Dose"},{"description":"Dose Escalation - Level 2 dose of 160 mg enzalutamide (orally) with standard dose of cisplatin and gemcitabine via intravenous (IV).","id":"OG001","title":"Dose Escalation: Level 2 Dose"},{"description":"Dose Expansion: Enzalutamide at MTD (160 mg) with standard doses of cisplatin and gemcitabine.","id":"OG002","title":"Dose Expansion"}],"paramType":"MEDIAN","populationDescription":"All Participants.","reportingStatus":"POSTED","timeFrame":"14 months","title":"Progression Free Survival (PFS)","type":"SECONDARY","unitOfMeasure":"months"}